A call for Expression of Interest to participate in EUnetHTA JA3 Early Dialogues has now been published.
We are pleased to announce that the 1st Collaborative Assessment of WP4 AC-B on “Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk” is ready now available.
The EC-EUnetHTA Forum "European cooperation on HTA: what's next?" co-organised by the European Commission and the EUnetHTA Joint Action 3 was the first meeting between all 79 EUnetHTA partner organisations and the broader HTA stakeholder community.
The Forum entitled “European Cooperation on HTA: What’s next?” is jointly organized by the European Commission and EUnetHTA and EC on the 21st of October 2016 in Brussels (The Square conference center).
On the 7th June 2016, a technical meeting was held in Paris, hosted by Haute Autorité de Santé (HAS, EUnetHTA Work Package 5 lead). The participants of this meeting not only included all EUnetHTA Joint Action 3 WP leads, but also representatives from industry (pharmaceutical), European Federation of Pharmaceutical Industries and Associations (EFPIA), European Medicines Agency (EMA), HTA agencies and the European Commission.